Trial Profile
Efficacy and safety of FYX-051 in hyperuricemic patients with moderate renal insufficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jun 2016
Price :
$35
*
At a glance
- Drugs Topiroxostat (Primary)
- Indications Hyperuricaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Fuji Yakuhin; Sanwa Kagaku Kenkyusho
- 01 Jun 2016 New trial record